Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Poly(ADP-ribose) polymerase inhibitors (PARPis) improved advanced ovarian cancer treatment. Most patients progress during or following PARPi exposure, however, with concerns about sensitivity of subsequent chemotherapy.

Read Full Paperexternally

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

Cite This Study

Xu-Vuillard et al. (Sun,) studied this question.

synapsesocial.com/papers/68e59c56b6db6435875369ce https://doi.org/https://doi.org/10.1016/j.esmoop.2024.103694

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer.2022 · 14 citations